Hôpital Bichat
Paris, 75018, France
NCT Number: NCT01311765
The investigators purpose is to demonstrate that a short antibiotic therapy (8 days) for postoperative peritonitis brings an increased number of antibiotic-free days over a 28 days period when compared to conventional (15 days) treatment.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Paris, 75018, France
This is a prospective randomized study involving 25 centers. Our goal is to demonstrate in the course of postoperative peritonitis that a short antibiotic therapy (8 days) compared to conventional antibiotic treatment (15 days) decreases the duration of exposure to antibiotics over a 28 days period . Patients admitted in ICU, operated for postoperative peritonitis and receiving an adequate antibiotic therapy will be identified and after informed consent is obtained will be randomized to receive a short course of antibiotic therapy (8 days) or a long course of antibiotic therapy (15 days). The primary endpoint is the number of antibiotic-free days at D28 after inclusion (analysis of superiority) . Secondary endpoints include mortality at D45 after inclusion (analysis of equivalence), the occurrence of relapse of infection, success rate of clinically and microbiologically evaluable patients, and emergence of multidrug resistant microorganisms in clinical isolates or hygiene samples. Patient data through day 45 following the initial intervention or until hospital discharge will be tracked.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The eligible patients have to fulfill all the following criteria
Non-inclusion criteria :
Patients with one of the following criteria are eligible for the study :
Secondary exclusion criteria:
Among the eligible patients, those who have one of the following criteria will be excluded
Initiation of adequate empiric antibiotics for postoperative peritonitis within 24 hours after surgery and up to 8 days. At randomisation performed on day 8, the patients assigned to the 8-day group (short-course group) stop their treatment
Time frame: 28 days
The number of antibiotic-free days at D28 after inclusion (analysis of superiority)
Time frame: 45 days
Mortality at D45 after inclusion (analysis of equivalence)
Time frame: 45 days
Duration of ICU and hospital stay
Time frame: 8 days
Changes in SOFA score
Time frame: 28 days
Number of days alive without organ failure
Time frame: 28 days
Failure rate for clinically evaluable patients
Time frame: 28 days
Failure rate for microbiologically evaluable patients
Time frame: 45 days
Rate of relapse within 45 days
Time frame: ICU discharge
Emergence of multidrug resistant microorganisms in clinical isolates and hygiene samples
Time frame: 28 days
Total cost of antibiotic agents
Time frame: 15 days
Evolution of procalcitonin plasma concentration
Time frame: 45 days
Rate of death within 45 days in specific subpopulations (elderly patients >80 years ; morbidly obese patients BMI>25kg/m2 ; severe infection with SAPSII score >40 ;peritoneal infection involving pseudomonas or enterococci ; bacteriemic infections)
Time frame: Hospital discharge
Total cost of hospital stay and evaluation of costs and resources impact for the hospital administration
Assistance Publique - Hôpitaux de Paris
Other
Comparison of Two Durations of Antibiotic Therapy in the Treatment of Severe Postoperative Peritonitis Admitted in Intensive Care Unit: a Randomised Multicentre Study
Acronym: DURAPOP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00965848
Bacterial Infections, Bacterial Infections and Mycoses
Bangkok, Thailand
View Trial DetailsNCT01763008
Bacterial Infections, Bacterial Infections and Mycoses
Cebu, Philippines
View Trial DetailsNCT07689266
Digestive System Diseases, Gastrointestinal Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07687251
Accidental Falls, Acute Care Unit
Cuneo, Italy
View Trial Details